Puma Biotechnology, Inc. (PBYI) earnings
Puma Biotechnology, Inc. (PBYI) reported net income of $31.11M in fiscal 2025 (the year ended December 31, 2025). That is 2.8% higher than the $30.28M of fiscal 2024. Figures as of 18 Nov 2026, 11:14 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Earnings (net income), fiscal 2025
- $31.11M
- Change on fiscal 2024
- +2.8%
- Highest on record
- $31.11Mfiscal 2025
- Lowest on record
- -$291.96Mfiscal 2017
- Fiscal years on record
- 152011–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Puma Biotechnology, Inc. earnings, in more detail
Across the 15 fiscal years on record (2011–2025), the highest was $31.11M in fiscal 2025 and the lowest -$291.96M in fiscal 2017.
Earnings (net income) by fiscal year
Puma Biotechnology, Inc. earnings, year by year
| Fiscal year | Earnings (net income) | Change | Year ended |
|---|---|---|---|
| 2025 | $31.11M | 2.8% up | |
| 2024 | $30.28M | 40.2% up | |
| 2023 | $21.59M | 1,079,450.0% up | |
| 2022 | $2.00K | — | |
| 2021 | -$29.13M | — | |
| 2020 | -$60.00M | — | |
| 2019 | -$75.60M | — | |
| 2018 | -$113.58M | — | |
| 2017 | -$291.96M | — | |
| 2016 | -$276.01M | — | |
| 2015 | -$239.28M | — | |
| 2014 | -$141.97M | — | |
| 2013 | -$54.66M | — | |
| 2012 | -$74.35M | — | |
| 2011 | -$10.23M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.
How to read it
Compare it across years rather than in isolation — one-off gains and write-downs can swing a single year a long way.
Puma Biotechnology, Inc., figure by figure
- Puma Biotechnology, Inc. market cap
- Puma Biotechnology, Inc. revenue
- Puma Biotechnology, Inc. earnings per share (EPS)
- Puma Biotechnology, Inc. P/E ratio
- Puma Biotechnology, Inc. P/S ratio
- Puma Biotechnology, Inc. P/B ratio
- Puma Biotechnology, Inc. free cash flow
- Puma Biotechnology, Inc. operating margin
- Puma Biotechnology, Inc. dividend
- Puma Biotechnology, Inc. shares outstanding
- Puma Biotechnology, Inc. total debt
- Puma Biotechnology, Inc. cash on hand
- Puma Biotechnology, Inc. total assets
- Puma Biotechnology, Inc. return on equity (ROE)
- Puma Biotechnology, Inc. return on invested capital (ROIC)
Puma Biotechnology, Inc. (PBYI) overview: price, valuation and scorecard
Puma Biotechnology, Inc. earnings: questions and answers
What is Puma Biotechnology, Inc.'s net income?
Puma Biotechnology, Inc. (PBYI) reported net income of $31.11M in fiscal 2025 (the year ended December 31, 2025). That is 2.8% higher than the $30.28M of fiscal 2024.
What are the highest and lowest net income figures on record for Puma Biotechnology, Inc.?
Across the 15 fiscal years on record (2011–2025), the highest was $31.11M in fiscal 2025 and the lowest -$291.96M in fiscal 2017.
How is Puma Biotechnology, Inc.'s net income calculated?
Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement. For Puma Biotechnology, Inc. it is on record here for 15 fiscal years, 2011 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: earnings
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Puma Biotechnology, Inc. (PBYI) earnings”, data as of 18 November 2026. https://funkfolio.com/stock/PBYI/earnings
Underlying data: the company's filings with the SEC and Yahoo Finance.